Refine by
Preclinical Data Equipment & Supplies In In Canada
24 equipment items found
Manufactured by:Tectonic Therapeutic, Inc. based in
AVROBIO has a preclinical research program for mucopolysaccharidosis type II (MPS II), or Hunter syndrome. The program is being developed in collaboration with Brian Bigger, Ph.D., who has published favorable preclinical data in a mouse model of Hunter ...
Manufactured by:Virpax Pharmaceuticals based inBerwyn, PENNSYLVANIA (USA)
Kappa and delta opioid agonists have been shown to provide analgesic benefit while sparing mu agonist toxicity1. Preclinical data supports analgesia from enkephalin without significant opioid tolerance or drug liking. Typically, exogenous enkephalins are rapidly degraded and have difficulty accessing the CNS2. Using a novel encapsulation method known as Molecular ...
by:Enveric Biosciences, Inc. based inNaples, FLORIDA (USA)
Enveric Biosciences seeks to advance novel combinations of CBD with chemotherapeutic agents and immunotherapies. Preclinical data suggests combination therapies may improve the activity of certain chemotherapies or cancer immunotherapies, potentially enabling more potent or longer-lasting therapeutic effects. In addition, combination therapies may allow for the ...
Manufactured by:Frontier Biotechnologies Inc. based inNanjing, CHINA
It is a peptidomimetic compound targeting 3CL-protease based on three-dimensional crystal structure of the protease. Preclinical data has shown it has potent activities in vitro and in vivo against SARS-CoV-2 variants such as Alpha, Beta, Delta, and Omicron. Clinical data from two phase 1 trials conducted in the US and China has shown that ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
What differentiates this therapy from our ADP-A2M4 SPEAR T-cells is that these cells also express the CD8α co-receptor alongside the engineered TCR that targets MAGE-A4. Preclinical data indicate that co-expression of CD8α may broaden the immune response against solid tumors and increase anti-tumor activity by leveraging CD4+ cells into CD8+ killer or ...
Manufactured by:Biosceptre International Limited based inCambridge, UNITED KINGDOM
We are also developing antibodies that specifically target nfP2X7 for use in both solid and haematological tumours. Our preclinical data is very promising and studies show an excellent safety profile. By exploiting the modular nature of the antibody structure, the same panel of antibody sequences can be used to generate a variety of therapeutic antibody formats ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
Stimulator of Interferon Genes (STING) is a well-studied innate immune pathway capable of inducing anti-tumor immune activity. Our preclinical data show that the anti-tumor activity of Immunosynthen STING-agonist ADCs involves the targeted activation of the STING pathway in both tumor-resident immune cells and in tumor cells, in an antigen binding-dependent ...
Distributed by:LT Scientific, Inc. based inCarson City, NEVADA (USA)
The Agilent Discovery MR901 System provides a high quality and robust pre-clinical MRI research environment operated via a powerful and intuitive GE clinical user interface. Produced in association with GE Healthcare the Discovery MR901 System is optimized for pre-clinical imaging at 7T enabling not only straightforward operation by clinical-familiar staff, but simple and relevant comparison of ...
Manufactured by:ASC Therapeutics based inMilpitas, CALIFORNIA (USA)
Stem cells, including inducible pluripotent stem cells, mesenchymal stem cells (MSCs) and other primary pluripotent cells, hold the potential to treat a variety of diseases. We are currently focusing on developing an allogeneic decidua stromal cells (DSCs)-based platform to treat severe immune-mediated diseases. Our pre-clinical and clinical data suggest that the immunomodulatory activity of DSCs ...
Manufactured by:Affimed GmbH based inHeidelberg, GERMANY
Lighting the way with clinical results: we are creating success with monotherapies and combination therapies. AFM13, a first-in-class ICE (innate cell engager) molecule targeting patients with CD30-positive lymphomas,4 showed antitumor responses in a Phase 1/2 trial as a monotherapy in 15 patients with T-cell lymphomas and cutaneous involvement (44% ORR).5 When used in combination with allogeneic ...
Manufactured by:Sequana Medical NV based inSint-Denijs Westrem, BELGIUM
Direct Sodium Removal (DSR®) therapy is Sequana Medical’s novel and proprietary approach under development for the management of fluid overload due to heart failure. The sodium concentration in patients with fluid overload is in balance but there is too much sodium and too much fluid in the body. Sequana Medical’s approach is to remove excess sodium in patients with ...
Manufactured by:Applied Pharma Research s.a. based inBalerna, SWITZERLAND
APR TD012 is a clinical stage drug candidate for the treatment of wounds in Hailey Hailey Disease (HHD) patients. The product improves healing process thanks to its bioburden control and its anti-oxidant properties.Oxidative stress has been demonstrated to play a specific role in the pathogenesis of HHD by regulating the expression of factors playing an important role in keratinocyte ...
Manufactured by:Affimed GmbH based inHeidelberg, GERMANY
AFM24, an EGFR-directed ICE® (innate cell engager) molecule, represents a distinctive mechanism that engages innate immune cells by recruiting NK cells and macrophages to the site of the tumor for effective and efficient tumor-cell killing. Potential to treat various solid tumor types with a more acceptable safety profile while remaining immune to the challenge of ...
by:Procarta Biosystems Ltd based inNorwich, UNITED KINGDOM
Proprietary nanoparticles deliver an oligonucleotide inside the bacterial pathogen. The oligonucleotide acts as a Transcription Factor Decoy (TFD): it contains the binding site of a transcription factor that controls a large set of genes required for the survival of the bacterium. The TFD acts as a competitive inhibitor to prevent these genes being turned on and so prevents growth and treats the ...
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
IVX-411 targets SARS-CoV-2, the coronavirus that causes COVID-19. Developed using cutting-edge structure-based design techniques at the Institute for Protein Design at the UW School of Medicine, IVX-411, our lead vaccine candidate for COVID-19, is a self-assembling protein nanoparticle that displays 60 copies of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain (RBD) in a highly ...
Manufactured by:Meissa Vaccines, Inc. based inRedwood City, CALIFORNIA (USA)
Meissa is developing a live attenuated COVID-19 vaccine candidate, MV-014-212, to induce mucosal and systemic immunity and protect against SARS-CoV-2, the novel coronavirus that causes COVID-19. Like Meissa’s RSV vaccine candidate, MV-014-212 offers significant potential advantages for global deployment, including needle-free intranasal administration, a single adjuvant-free dose to induce ...
Manufactured by:Orchestra BioMed, Inc. based inNew Hope, PENNSYLVANIA (USA)
BackBeat CNT™ is a patented bioelectronic treatment for hypertension that is designed to drive an immediate, substantial and persistent reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain lowered blood pressure long-term. A patented, intelligent bioelectronic treatment for hypertension. BackBeat Cardiac Neuromodulation Therapy is ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
ADCs are not one-size-fits-all. The Dolasynthen platform enables an iterative approach to develop the right ADC for a given indication through customization and optimization. Dolasynthen utilizes a synthetic scaffold for precise control of DAR (from 2-24) and site-specific antibody bioconjugation. The platform is also able to homogeneously generate ADCs with precisely defined DARs for consistent ...
Manufactured by:Elpiscience based inShanghai, CHINA
ES104 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization. VEGF also plays an important role in creating an immune suppressive TME. Pre-clinical and early clinical data of ES104 show that blocking both pathways provides robust ...
Manufactured by:BRIM Biotechnology, Inc. based inTaipei City, TAIWAN
Novel drugs to relieve and repair tissue damage caused by osteoarthritis. BRIM Biotechnology is developing novel drugs to relieve and repair tissue damage caused by osteoarthritis. BRM521’s unique mechanism of action promotes joint cartilage regeneration and relieves ...